HSINCHU, July 3, 2025 /PRNewswire/ -- Gwo Xi Stem Cell Applied Technology Co., Ltd. (TPEx: 6704) is a clinical-stage cell therapy company headquartered in...
The Leukemia & Lymphoma Society's Scenic Shore Bike Tour Offers a Unique Ride Experience to Help Advance Lifesaving Research, Support, and Advocacy
WASHINGTON, July 2,...
The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....
The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....
BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) -- The two leading academic institutions have joined forces with TulsiHub Institute, the premier provider of advanced CE certified regenerative medicine certification programs, to transform medical education standards across regenerative medicine and cellular therapy disciplines. This innovative alliance positions both universities as pioneers in cutting-edge healthcare training while establishing new industry standards for professional medical certifications and continuing medical education in the rapidly expanding regenerative healthcare sector.
BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) -- The two leading academic institutions have joined forces with TulsiHub Institute, the premier provider of advanced CE certified regenerative medicine certification programs, to transform medical education standards across regenerative medicine and cellular therapy disciplines. This innovative alliance positions both universities as pioneers in cutting-edge healthcare training while establishing new industry standards for professional medical certifications and continuing medical education in the rapidly expanding regenerative healthcare sector.
Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules.
Multimillion-Dollar Investment Delivers New Adventure Amenities, Mountain Modern Real Estate Offerings and an Innovative Partnership with Renowned Integrative Medical Practice Clinic 5C
COEUR D'ALENE, Idaho,...
Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells
AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...
Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes
CHICAGO, June 20, 2025 /PRNewswire/ -- Findings from two studies...